KRAS and neoplasm: Interestingly, Seguin et al. showed that activation of the integrin αvβ3 complex by non-canonical ligand galectin-3 binding recruits KRAS to the tumor cell plasma membrane, which in turn results in a prominent RalB and NF-κB activation7.